Advanced Pain Therapeutics (APT), a new strategic development company formed by Cato Research, Advanced Targeting Systems (ATS), and Cato BioVentures, the venture capital affiliate of Cato Research, obtained exclusive, worldwide rights to develop, manufacture, use, and sell SP-SAP for the treatment of severe chronic pain. Cato Research will provide contract research organization services to the new company.
Denise Higgins, vice president of ATS, said: “We are enthusiastic about working with APT and Cato Research to help address the under-served chronic pain population. Our preclinical work with SP-SAP makes us very optimistic about the impact this innovative treatment can have for those who are suffering.”